The goal of this clinical trial is to systematically evaluate whether peptide-type enteral nutrition (EN) formulations improve protein uptake efficiency in high-risk groups at ICU PEI, using targeted amino acid metabolomics and gut microbiota co-metabolomics as core quantitative indicators.
Researchers will compare protein absorption efficiency of short-chain peptide and complete protein enteral nutrition formulas in high-risk populations for PEI in the ICU
Participants will:
Enteral nutrition was administered for ICU critically ill patients with high-risk factors for PEI
Age≥ 18 years old, no gender restriction;
Meet the criteria for high-risk groups for PEI;
AGI≤ Class II, hemodynamically stable, meeting EN initiation criteria;
Estimated duration of enteral nutrition support therapy: ≥7 days;
Patients who have been clearly diagnosed with PEI or chronic persistent PEI;
Patients who have contraindications to enteral nutrition therapy;
Patients with severely impaired liver or kidney function;
Patients who suffer from amino acid metabolism disorders, severe malnutrition, or cachexia;
Shanghai 10th People's Hospital
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Sponsor institution